Connect with us

Business

Eli Lilly hikes price of diabetes drug Mounjaro in UK as Trump pressures pharma to align drug costs

Published

on

Eli Lilly hikes price of diabetes drug Mounjaro in UK as Trump pressures pharma to align drug costs


Mounjaro manufactured by Eli Lilly and Company packaging is seen in this illustration photo taken in a pharmacy in Krakow, Poland on April 9, 2024.

Nurphoto | Nurphoto | Getty Images

Eli Lilly on Thursday said it is raising the list price of its blockbuster diabetes drug Mounjaro in the U.K. starting in September, as President Donald Trump pressures drugmakers to lower U.S. drug prices and hike them abroad.

In a statement, Eli Lilly said it reached an agreement with the U.K. government to increase the list price of the weekly injection, while “maintaining access” for patients covered under the publicly funded health-care system, the National Health Service, or NHS. 

Eli Lilly told CNBC that the price hike will not affect the drug’s availability under NHS, and it wants to work with the government to boost access. The company added that it does not determine prices that private health-care providers set, but is working with them to ensure access to Mounjaro. 

In a statement on Thursday, NHS said Mounjaro’s list price increase “will not affect NHS commissioning of tirzepatide in England for eligible people living with obesity, based on clinical priority, or as a treatment for type 2 diabetes.” Tirzepatide is the active ingredient in Mounjaro and its counterpart for weight loss, Zepbound.

Mounjaro’s current list price in the UK ranges from £92 (about $124.89) to £122 a month, depending on the dose size, according to Eli Lilly. The drug’s new list price will increase to between £133 and £330 starting on Sept. 1. 

The company added that it is working with certain governments and expects to make pricing adjustments in those countries by that date. In the U.S., the list price for a month’s supply of Mounjaro is $1,079.77 before insurance and other rebates. 

Eli Lilly said it supports the Trump administration’s goal of keeping the U.S. the “world’s leading destination for biopharmaceutical research and manufacturing, and the objective of more fairly sharing the costs of breakthrough medical research across developed countries.” 

“This rebalancing may be difficult, but it means the prices for medicines paid by governments and health systems need to increase in other developed markets like Europe in order to make them lower in the US,” the company said in the statement.

The announcement comes after Trump in July sent separate letters to 17 drugmakers, including Eli Lilly, calling on them to take steps to lower drug prices by Sept. 29. The move built on the president’s executive order in May reviving a controversial plan – the “most favored nation” policy – that aims to slash drug costs by tying the prices of some medicines in the U.S. to the significantly lower ones abroad.

U.S. prescription drug prices are two-to-three times higher on average than those in other developed nations – and up to 10 times more than in certain countries, according to the Rand Corp., a public policy think tank. Trump has said he wants to narrow that gap to stop Americans from being “ripped off.”

Eli Lilly’s announcement on Thursday comes as the industry braces for Trump’s planned tariffs on pharmaceuticals imported into the U.S. In its statement, the company said it opposes those tariffs, arguing they will “raise costs, limit patient access, and undermine American leadership, especially for companies already investing heavily in domestic manufacturing.”

In recent months, Eli Lilly was among several drugmakers to announce new plans to invest in U.S. manufacturing sites.



Source link

Business

Pine Labs, Groww & more: Top stocks to watch on April 16 – The Times of India

Published

on

Pine Labs, Groww & more: Top stocks to watch on April 16 – The Times of India


Citigroup initiated its coverage of Pine Labs with a buy rating and a target price of Rs 235. Analysts said that India’s payments fintech is on a monetization improvement trajectory, with leading players increasingly entrenched in respective core areas of leadership. While product, services and distribution build-outs into comprehensive plays will continue across the fintech ecosystem, large players don’t face significant disruption risks owing to: Across-the-board profitability push; rising regulatory costs and compliance requirements; and stickiness borne out of integration into enterprise business workflows. Further, while consumer payments have seen flux in competitive positioning in the past decade, there have been relatively fewer changes in positioning and leadership within segments in merchant payments.BoFA Securities has initiated its coverage of Groww (Billionbrains Garage Ventures) with a buy rating and a target price of Rs 235. Analysts said Groww is well positioned to capitalize on India’s retail investing tailwinds and they expect compounded annual growth rate (CAGR) for revenue at 30% over FY26-FY28. The company produces best-in-class profitability with further upside from operating leverage. Analysts have valued Groww at 39x FY28E price-to-earnings. They, however, said that the near-term risks for the stock are a weak capital market performance and the expiry of the six-month lock-in of shares post-IPO.Elara Capital initiated its coverage of Jindal Saw with a buy rating and a target price of Rs 280. Analysts said earnings recovery is expected over FY27–FY28, driven by water, and oil & gas demand. The company’s order book is at an all-time high, indicating strong visibility. They also feel Jal Jeevan Mission spending revival to drive domestic pipe demand, while the global pipeline capex is supported by energy security concerns. Analysts also pointed out that exports are rising, with diversification reducing dependence on domestic capex. The company’s capacity expansion to support margins and operating leverage. They feel the stock’s valuations are attractive, with rerating potential driven by execution and growth.Jefferies has downgraded Indus Towers to underperform from buy with a target price cut to Rs 375 from Rs 530. Analysts downgrade the stock due to site-renewal risks bunched up over second half of 2026 (H2CY26) and first half of 2027 (H1CY27) which could impact revenues and growth. Elevated capex levels due to higher growth and maintenance capex which will impact earnings growth as well free cash flow and payouts. They cut Indus Towers’ revenue and profit after tax (PAT) estimates by 2-6% to factor renewal risks post which stock offers 3% EPS growth and a 4% yield. They said risks on growth outlook should weigh on re-rating potential too.Kotak Institutional Equities has a buy on Ujjivan SFB with a target price of Rs 72. Analysts said that the RBI has returned Ujjivan SFB’s application for a universal bank license, citing need for further loan portfolio diversification. While the outcome is clearly not favourable, the regulator has flagged no concerns relating to governance, compliance or operational soundness. Analysts said their investment thesis did not factor in any benefit from a potential transition to a universal bank. Hence, they maintained a buy but remained watchful of any sharp changes in asset mix strategy in response to RBI’s feedback.(Disclaimer: Recommendations and views on the stock market, other asset classes or personal finance management tips given by experts are their own. These opinions do not represent the views of The Times of India)



Source link

Continue Reading

Business

China’s hits economic growth target despite Iran war disruption

Published

on

China’s hits economic growth target despite Iran war disruption



The better-than-expected GDP data comes as Asian countries have been hit hard by the impact of the conflict.



Source link

Continue Reading

Business

Geelong fire: Blaze at Australian oil refinery to impact petrol supplies

Published

on

Geelong fire: Blaze at Australian oil refinery to impact petrol supplies



The fire has deepened fears over the nation’s petrol supplies amid a global crunch.



Source link

Continue Reading

Trending